NCT00708318View on ClinicalTrials.gov

Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

November 30, 2001

Study Completion Date

June 30, 2002

Conditions
Healthy
Interventions
DRUG

i.v. fentanyl and AeroLEF

"Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).~Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN."

Trial Locations (1)

M1L4S4

University of Toronto, Toronto

Sponsors

Lead Sponsor

YM BioSciences
All Listed Sponsors
lead

YM BioSciences

INDUSTRY

NCT00708318 - Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects | Biotech Hunter | Biotech Hunter